Assertio Holdings to be Acquired by Zydus Worldwide DMCC for $23.50/Share in All-Cash Tender Offer

summarizeSummary

Assertio Holdings, Inc. has entered into a definitive agreement to be acquired by Zydus Worldwide DMCC for $23.50 per share in an all-cash tender offer, replacing a prior agreement with Garda Therapeutics.

check_boxKey Events

• Definitive Acquisition Agreement

  Assertio Holdings, Inc. has entered into an Agreement and Plan of Merger with Zydus Worldwide DMCC for an all-cash tender offer of $23.50 per share.

• Total Consideration

  The acquisition is valued at approximately $166.4 million, representing a full buyout of the company.

• Significant Premium

  The offer price of $23.50 per share represents a 75.8% premium to the company's unaffected closing stock price on March 20, 2026, and a 7.8% premium to the previously amended Garda offer of $21.80 per share.

• Board Unanimously Recommends Offer

  Assertio's Board of Directors has unanimously approved the merger and recommends that stockholders tender their shares into the Zydus offer.

auto_awesomeAnalysis

This filing formalizes the definitive agreement for Zydus Worldwide DMCC to acquire Assertio Holdings, Inc. for $23.50 per share in an all-cash tender offer, totaling approximately $166.4 million. This represents a significant premium over previous offers and the unaffected stock price, indicating a highly favorable outcome for shareholders. The transaction also involves the termination of the prior merger agreement with Garda Therapeutics, with Zydus covering the associated termination fee. The Board's unanimous recommendation underscores the conviction in this superior proposal, which will result in Assertio becoming a wholly-owned subsidiary of Zydus.